Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases
Status:
Completed
Trial end date:
2016-05-30
Target enrollment:
Participant gender:
Summary
This study is to find an optimal dose of Imiquimod (IMQ) in the first part (Phase I) and test
the effectiveness of the combination treatment of IMQ, cyclophosphamide (CTX), and
radiotherapy (RT) in patients with skin metastases from breast cancer in the second part
(Phase II). Currently this trial is in its Phase II part.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
New York University School of Medicine NYU Langone Health